Fennec Pharmaceuticals (FENC) Non-Current Deffered Revenue: 2023-2025
Historic Non-Current Deffered Revenue for Fennec Pharmaceuticals (FENC) over the last 2 years, with Sep 2025 value amounting to $24.6 million.
- Fennec Pharmaceuticals' Non-Current Deffered Revenue changed negligibly% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $24.6 million for FY2024, which is 1227950.00% up from last year.
- Fennec Pharmaceuticals' Non-Current Deffered Revenue amounted to $24.6 million in Q3 2025, which was down 0.00% from $24.6 million recorded in Q2 2025.
- In the past 5 years, Fennec Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $25.0 million in Q1 2024 and a low of $2,000 during Q4 2023.
- For the 3-year period, Fennec Pharmaceuticals' Non-Current Deffered Revenue averaged around $21.6 million, with its median value being $24.6 million (2025).
- In the last 5 years, Fennec Pharmaceuticals' Non-Current Deffered Revenue skyrocketed by 1,227,950.00% in 2024 and then dropped by 1.73% in 2025.
- Over the past 3 years, Fennec Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $2,000 in 2023, then soared by 1,227,950.00% to $24.6 million in 2024, then remained steady at $24.6 million in 2025.
- Its Non-Current Deffered Revenue was $24.6 million in Q3 2025, compared to $24.6 million in Q2 2025 and $24.6 million in Q1 2025.